Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 17/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2669656 | 0.90 | OPRL1 (0.40) | CXCR4KCNH2 | |
| SCHEMBL25515629 | 0.90 | OPRL1 (0.40) | CXCR4KCNH2 | |
| SCHEMBL1698222 | 0.84 | CXCR4 (0.44) | CXCR4CYP2D6KCNH2 | |
| SCHEMBL30667255 | 0.83 | CXCR4 (0.42) | CXCR4CYP2D6KCNH2 | |
| SCHEMBL1698248 | 0.83 | CXCR4 (0.42) | CXCR4CYP2D6KCNH2 | |
| SCHEMBL1698217 | 0.83 | CXCR4 (0.42) | CXCR4CYP2D6KCNH2 | |
| SCHEMBL1698196 | 0.82 | CXCR4 (0.43) | CXCR4CYP2D6KCNH2 | |
| SCHEMBL5021377 | 0.82 | HDAC1 (0.42) | CXCR4CYP2D6KCNH2 | |
| SCHEMBL12070440 | 0.80 | CXCR4 (0.41) | CXCR4CYP2D6KCNH2 | |
| SCHEMBL1698226 | 0.79 | CXCR4 (0.41) | CXCR4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103159676-A | Compounds and application thereof | LU ZHONGLIN | 2013-06-19 | — | — | CN | claimed |
| WO-2024059096-A2 | C5AR1 ANTAGONISTS AND USES THEREOF | VANQUA BIO, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20230183188-A1 | ENPP1 MODULATORS AND USES THEREOF | Vir Biotechnology, Inc. | 2023-06-15 | — | — | US | disclosed |
| US-20230183188-A1 | ENPP1 MODULATORS AND USES THEREOF | Vir Biotechnology, Inc. | 2023-06-15 | — | — | US | disclosed |
| WO-2021231726-A1 | ENPP1 MODULATORS AND USES THEREOF | Vir Biotechnology, Inc. (US) | 2021-11-18 | — | — | WO | disclosed |
| US-11001579-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2021-05-11 | — | — | US | disclosed |
| US-10738041-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2020-08-11 | — | — | US | disclosed |
| US-20190345151-A1 | Novel Ferroportin Inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2019-11-14 | — | — | US | disclosed |
| US-20190290771-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2019-09-26 | — | — | US | disclosed |
| US-20190144396-A1 | 9-MEMBERED FUSED RING DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2019-05-16 | — | — | US | disclosed |
| US-20100113516-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113516-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100105659-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPPHARMA INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100029634-A1 | Chemokine Receptor Modulators | ALTIRIS THERAPEUTICS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029634-A1 | Chemokine Receptor Modulators | ALTIRIS THERAPEUTICS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20080293711-A1 | Chemokine receptor modulators | METASTATIX, INC. | 2008-11-27 | — | — | US | disclosed |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2008109154-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20070003680-A1 | Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers | SENOMYX, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070003680-A1 | Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers | SENOMYX, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190345151-A1 | Novel Ferroportin Inhibitors | HAMP, SLC40A1, HMOX1 | CXCR4 2203/4885CYP2D6 278/4885KCNH2 4249/4885 |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | MKI67, CCNI, CDKN1A | CXCR4 242/4885CYP2D6 962/4885KCNH2 3768/4885 |
| US-10738041-B2 | Ferroportin inhibitors | SLC40A1, HAMP, TFRC | CXCR4 3358/4885CYP2D6 1462/4885KCNH2 4148/4885 |
| US-20190290771-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | CXCR4 2552/4885CYP2D6 2628/4885KCNH2 4754/4885 |
| US-11001579-B2 | Ferroportin inhibitors | HAMP, SLC40A1, FTH1 | CXCR4 2211/4885CYP2D6 264/4885KCNH2 4378/4885 |
| US-20080293711-A1 | Chemokine receptor modulators | CCR5, CCL2, CXCR4 | CXCR4 3/4885CYP2D6 2999/4885KCNH2 4757/4885 |
| US-20100105659-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | GCK, GCKR, GALK1 | CXCR4 4576/4885CYP2D6 1381/4885KCNH2 982/4885 |
| US-20100113516-A1 | QUINOLYNYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS | TUBB3, TUBB1, NQO2 | CXCR4 1716/4885CYP2D6 1003/4885KCNH2 2610/4885 |
| US-20190144396-A1 | 9-MEMBERED FUSED RING DERIVATIVE | ACSS2, AGTR2, ACSL3 | CXCR4 4008/4885CYP2D6 359/4885KCNH2 651/4885 |
| US-20230183188-A1 | ENPP1 MODULATORS AND USES THEREOF | ENPP1, ENPP2, ENPP3 | CXCR4 2527/4885CYP2D6 3376/4885KCNH2 3531/4885 |
| US-20100029634-A1 | Chemokine Receptor Modulators | CCR5, CXCR4, ACKR3 | CXCR4 2/4885CYP2D6 2232/4885KCNH2 4846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.